subject area of
- A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer Journal Articles
- A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer Journal Articles
- A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab Journal Articles
- Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety? Journal Articles
- Adjuvant trastuzumab for HER2-positive breast cancer Journal Articles
- Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academia—A Roadmap for Overcoming Perceived Barriers Journal Articles
- An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction Journal Articles
- Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population Journal Articles
- Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy Journal Articles
- Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial Journal Articles
- Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma Journal Articles
- Clinical Practice Guidelines in Cardio-Oncology Journal Articles
- DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study Journal Articles
- Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones Journal Articles
- Early and late changes in markers of aortic stiffness with breast cancer therapy Journal Articles
- Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer Journal Articles
- Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial Journal Articles
- European oncologists' preferences for the management of breast cancer: case presentations and expert commentary Journal Articles
- Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab Journal Articles
- HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab Journal Articles
- Herceptest: Her2 expression and gene amplification in non-small cell lung cancer Journal Articles
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31 Journal Articles
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial Journal Articles
- Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers Journal Articles
- Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab Journal Articles
- Novel method for differentiation between Trastuzumab and host adaptive response Journal Articles
- Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial Conferences
- Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey Journal Articles
- Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer Journal Articles
- Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity Journal Articles
- Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel Journal Articles
- Pharmacologic insights into the future of trastuzumab. Conferences
- Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer Cells Journal Articles
- Preparative separation of monoclonal antibody aggregates by cation-exchange laterally-fed membrane chromatography Journal Articles
- Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression Journal Articles
- Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective Journal Articles
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Journal Articles
- Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab Journal Articles
- Trastuzumab Cardiac Side Effects: Only Time Will Tell Journal Articles
- Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study Journal Articles
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Journal Articles